Neumora Therapeutics, Inc.

NEWS

Pictured: A silhouette of a woman sitting on the f

Neumora Races Toward Phase III with New Driver in the Hot Seat

Less than two years after launch, the startup posts positive Phase II results and heads into Phase III trials for major depressive disorder with a new CEO.

July 18, 2023

2 min read

Kate Goodwin

Business

Top Life Sciences Startups to Watch in 2023

BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.

December 5, 2022

15 min read

BioSpace Editorial Staff

AWARDS

JOBS

IN THE PRESS

Press Releases

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

April 29, 2025

1 min read

Press Releases

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

March 4, 2025

1 min read

Press Releases

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 4, 2025

11 min read

Press Releases

Neumora Therapeutics Announces Leadership Transition

February 13, 2025

5 min read

Press Releases

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

January 2, 2025

8 min read

Press Releases

Neumora Therapeutics to Participate in Upcoming Conferences in November

November 6, 2024

1 min read

Press Releases

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

October 29, 2024

1 min read

Press Releases

Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders

August 15, 2024

6 min read

Press Releases

Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 6, 2024

10 min read

Drug Development

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

May 14, 2024

7 min read